Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 3 stocks made the list for top value stocks in the Health Care Providers & Services industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.
Why Focus on Undervalued Health Care Providers & Services Stocks?
Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.
AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
What Goes Into AAII’s Value Grade?
Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.
Click the button below to learn more about A+ Investor and subscribe today.
3 Undervalued Health Care Providers & Services Stocks
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Health Care Providers & Services industry for Wednesday, April 29, 2026. Let’s take a closer look at their individual scores to see how they measure up against each other and the Health Care Providers & Services industry median.
| Company | Ticker | Price/Sales | Price/Earnings | EV/EBITDA | Shareholder Yield | Price/Book Value | Price/Free Cash Flow | Value Grade |
| Aveanna Healthcare Holdings Inc. | AVAH | 0.55 | 6.4 | 8.5 | (8.1%) | 7.19 | 11.5 | B |
| Fulgent Genetics, Inc. | FLGT | 1.46 | na | 3.2 | (1.1%) | 0.43 | na | A |
| HCA Healthcare, Inc. | HCA | 1.39 | 15.2 | 9.0 | 10.3% | na | 14.6 | A |
The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.
The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)
Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).
As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.
Aveanna Healthcare Holdings Inc.’s Value Grade
Value Grade:
| Metric | Score | AVAH | Industry Median |
| Price/Sales | 20 | 0.55 | 1.01 |
| Price/Earnings | 6 | 6.4 | 23.7 |
| EV/EBITDA | 27 | 8.5 | 12.9 |
| Shareholder Yield | 73 | (8.1%) | (0.6%) |
| Price/Book Value | 85 | 7.19 | 2.48 |
| Price/Free Cash Flow | 28 | 11.5 | 17.7 |
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Aveanna Healthcare Holdings Inc. has a Value Score of 65, which is considered to be undervalued.
When you look at Aveanna Healthcare Holdings Inc.’s price-to-sales ratio at 0.55 compared to the industry median at 1.01, this company has a lower price relative to revenue compared to its peers. This could make Aveanna Healthcare Holdings Inc.’s stock more attractive for value investors.
Aveanna Healthcare Holdings Inc.’s price-earnings ratio is 6.40 compared to the industry median at 23.65. This means it has a lower share price relative to earnings compared to its peers. This could make Aveanna Healthcare Holdings Inc. more attractive for value investors.
Now, let’s assess Aveanna Healthcare Holdings Inc.’s EV/EBITDA ratio, also known as enterprise multiple. At 8.5, when compared to the industry median of 12.9, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.
Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Aveanna Healthcare Holdings Inc.’s shareholder yield is lower than its industry median ratio of (0.60%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.
As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Aveanna Healthcare Holdings Inc.’s price-to-book ratio is higher than its industry median ratio of 2.48. This could make Aveanna Healthcare Holdings Inc. less attractive to investors looking for a new addition to their portfolio.
Lastly, let’s take a look at Aveanna Healthcare Holdings Inc.’s price-to-free-cash-flow ratio (P/FCF), which can indicate a company’s market value relative to its operating cash flow. Aveanna Healthcare Holdings Inc.’s price-to-free-cash-flow ratio is lower than its industry median ratio of 17.70. This could make Aveanna Healthcare Holdings Inc. more attractive because the lower P/FCF ratio indicates that Aveanna Healthcare Holdings Inc. is undervalued. The P/FCF ratio metric can also be viewed over a long-term time frame to see if the company's cash flow to share price value is generally improving or worsening.
Fulgent Genetics, Inc.’s Value Grade
Value Grade:
| Metric | Score | FLGT | Industry Median |
| Price/Sales | 41 | 1.46 | 1.01 |
| Price/Earnings | na | na | 23.7 |
| EV/EBITDA | 6 | 3.2 | 12.9 |
| Shareholder Yield | 57 | (1.1%) | (0.6%) |
| Price/Book Value | 7 | 0.43 | 2.48 |
| Price/Free Cash Flow | na | na | 17.7 |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Fulgent Genetics, Inc. has a Value Score of 87, which is considered to be undervalued.
Fulgent Genetics, Inc.’s price-to-book ratio is higher than its peers. This could make Fulgent Genetics, Inc. less attractive for value investors when compared to the industry median at 2.48.
You can read more about Fulgent Genetics, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
HCA Healthcare, Inc.’s Value Grade
Value Grade:
| Metric | Score | HCA | Industry Median |
| Price/Sales | 39 | 1.39 | 1.01 |
| Price/Earnings | 37 | 15.2 | 23.7 |
| EV/EBITDA | 30 | 9.0 | 12.9 |
| Shareholder Yield | 4 | 10.3% | (0.6%) |
| Price/Book Value | na | na | 2.48 |
| Price/Free Cash Flow | 37 | 14.6 | 17.7 |
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
HCA Healthcare, Inc. has a Value Score of 85, which is considered to be undervalued.
HCA Healthcare, Inc.’s price-earnings ratio is 15.2 compared to the industry median at 23.7. This means that it has a lower price relative to its earnings compared to its peers. This makes HCA Healthcare, Inc. more attractive for value investors.
You can read more about HCA Healthcare, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Other Health Care Providers & Services Stock Grades
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.
Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Health Care Providers & Services stocks as well as other industrys.
Choosing Which of the 3 Best Health Care Providers & Services Stocks Is Right for You
Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.
- Aveanna Healthcare Holdings Inc. stock has a Value Grade of B.
- Fulgent Genetics, Inc. stock has a Value Grade of A.
- HCA Healthcare, Inc. stock has a Value Grade of A.
Now that you have a bit more background about each of the 3 undervalued stocks in the Health Care Providers & Services industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.
We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.
A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
Additional Resources About Health Care Providers & Services Stocks
Want to learn more about Health Care Providers & Services stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.
- 3 Undervalued Health Care Providers & Services Stocks for Wednesday, April 29
- Is UnitedHealth Group Incorporated (UNH) Overvalued?
- Which Is a Better Investment, Brookdale Senior Living Inc. or Universal Health Services, Inc. Stock?
- Which Is a Better Investment, Guardian Pharmacy Services, Inc. or Universal Health Services, Inc. Stock?
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
at only 23.3%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.